Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. White MN, et al.Clin Lung Cancer. 2021 May;…
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. White MN, et al.Clin Lung Cancer. 2021 May;…
この記事を読む
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Po…
この記事を読む
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Smal…
この記事を読む
Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Ret…
この記事を読む
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. Kalil AC et al.N Engl J Med.2021 Mar 4;384(9):795-807…
この記事を読む
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Pro…
この記事を読む
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. Hellyer JA et al.J…
この記事を読む
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. Faivre-F…
この記事を読む
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung canc…
この記事を読む
Psychosocial consequences of a three-month follow-up after receiving an abnormal lung cancer CT-screening result: A long…